-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Y-mAbs Therapeutics, Lowers Price Target to $15

Benzinga·05/29/2025 16:37:21
Listen to the news
Oppenheimer analyst Jeff Jones maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform and lowers the price target from $20 to $15.